Desidustat: Uses, interactions, mechanism of action | DrugBank Online. (n.d.). DrugBank. https://go.drugbank.com/drugs/DB16135
Dhillon, S. (2022). Desidustat: first approval. Drugs, 82(11), 1207–1212. https://doi.org/10.1007/s40265-022-01744-w
Agrawal, D., Varade, D., Shah, H., Nazar, A., Krishnan, J., Shukla, V., Ramakrishna, C., Galahitiyawa, M. C. B., Mavani, S. B., Rajanna, S., Jikki, P., De Silva, S., Ruhela, V., Koradia, P., Kansagra, K., Kanani, P., Sharma, N., Zala, K., & Parmar, D. (2022). Desidustat in Anemia due to Non-Dialysis-Dependent Chronic Kidney Disease: A Phase 3 Study (DREAM-ND). American Journal of Nephrology, 53(5), 352–360. https://doi.org/10.1159/000523961
Patel, V. J., Joharapurkar, A., Kshirsagar, S. G., Patel, M. S., Savsani, H. H., Dodiya, H. S., Rakhasiya, M. H., Kajavadara, C., Valani, D., & Jain, M. R. (2024). HIF-PHD inhibitor desidustat ameliorates iron deficiency anemia. Toxicology and Applied Pharmacology, 483, 116832. https://doi.org/10.1016/j.taap.2024.116832
Joharapurkar, A. A., Patel, V. J., Kshirsagar, S. G., Patel, M. S., Savsani, H. H., & Jain, M. R. (2021). Prolyl hydroxylase inhibitor desidustat protects against acute and chronic kidney injury by reducing inflammatory cytokines and oxidative stress. Drug Development Research, 82(6), 852–860. https://doi.org/10.1002/ddr.21792